Viropharma Inc Watch

ended 09/30/13 Q3

ended 06/30/13 Q2

ended 03/31/13 Q1

ended 12/31/12 FY 2012

ended 09/30/12 Q3

Issuer tender offer – amended

Securities registration termination

Removal from listing – amended

Removal from listing

Issuer tender offer – amended

Baker Felix

Palo Alto Investors LP

Fmr LLC

Vanguard Group Inc

BlackRock Finance, Inc.

Material Definitive Agreement, Termination of Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Increase/Acceleration of Financial Obligation or Off-Balance Sheet Arrangement, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Financial Statements or Exhibits

730 Stockton Drive Exton, Pennsylvania 19341 ViroPharma Incorporated

Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects

Reports Third Quarter 2013 Financial Results - Cinryze® (C1 Esterase Inhibitor [Human]) North American Net Sales Guidance Raised to $395 to $405 Million

Other Events

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Definitive proxy

Scanned paper annual report submission

Confidential treatment order

Letter from the SEC

Correspondence with the SEC

Letter from the SEC